Stockscreener 앱 받기
2.91
2.35%
-0.07
시간 외 거래:
2.89
-0.02
-0.69%
Clene Inc 주식(CLNN)의 최신 뉴스
Geode Capital Management LLC Grows Stake in Clene Inc. (NASDAQ:CLNN) - Defense World
Clene Inc. Enters Agreement for $25M Equity Distribution By Investing.com - Investing.com Nigeria
Clene Inc. Enters Agreement for $25M Equity Distribution - Investing.com Australia
Clene Inc.Enters Equity Distribution Agreement With CanaccordSEC Filing - marketscreener.com
Analysts Set Clene Inc. (NASDAQ:CLNN) Target Price at $55.25 - Defense World
Clene (NASDAQ:CLNN) Research Coverage Started at Jones Trading - Defense World
Clene (CLNN) Receives Buy Rating and $30 Target from JonesResear - GuruFocus
Clene (CLNN) Receives Buy Rating and $30 Target from JonesResearch | CLNN Stock News - GuruFocus
Clene to Present at the Emerging Growth Conference | CLNN Stock News - GuruFocus
Nanomedicines Market to Witness Massive Growth by 2032 | Abbott - openPR.com
Clene to Present at the Emerging Growth Conference - The Manila Times
Clene’s (CLNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Nanomedicines Market Generated Opportunities, Future Scope 2025-2032 | Abbott, CombiMatrix, Clene Nanomedicine - newstrail.com
Clene’s (CLNN) Buy Rating Reiterated at HC Wainwright - Defense World
Clene reports MS patient improvements with CNM-Au8 treatment By Investing.com - Investing.com India
Clene announces evidence of remyelination, neuronal repair with CNM-Au8 - TipRanks
Clene reports MS patient improvements with CNM-Au8 treatment - Investing.com Australia
Breakthrough: New MS Drug Actually Repairs Brain Damage, Trial Data Shows 90% Success Rate - Stock Titan
Clene (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference - The Globe and Mail
CLNN stock touches 52-week low at $2.95 amid market challenges By Investing.com - Investing.com South Africa
CLNN stock touches 52-week low at $2.95 amid market challenges - Investing.com India
Clene to Present at the Jones Healthcare and Technology Innovation Conference - The Manila Times
Clene Reveals Latest ALS and MS Treatment Innovations at Major Healthcare Conference - Stock Titan
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Roth Capital Has Negative Estimate for Clene Q1 Earnings - Defense World
Clene Inc. settles debt with equity issuance - Investing.com
Clene Inc.'S (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available For On-Demand Viewing - MENAFN.COM
Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings - Defense World
Research Analysts Issue Forecasts for Clene Q1 Earnings - Defense World
Clene (NASDAQ:CLNN) Earns Buy Rating from D. Boral Capital - The AM Reporter
What is HC Wainwright’s Estimate for Clene FY2028 Earnings? - Defense World
Clene stock touches 52-week low at $3.8 amid market challenges - Investing.com Australia
Clene stock touches 52-week low at $3.8 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $31 target on Clene stock post-results By Investing.com - Investing.com Canada
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 - StreetInsider.com
H.C. Wainwright maintains $31 target on Clene stock post-results - Investing.com
Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright - Defense World
Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Clene Inc. Reports 2024 Financial Results and Strategic Plans - TipRanks
Clene Inc (CLNN) Reports Q4 EPS of -$5.67, Revenue of $0.36M, Mi - GuruFocus
Clene Inc. Files For Mixed Shelf Of Up To $160 MillionSEC Filing -March 24, 2025 at 04:51 pm EDT - MarketScreener
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data - Barchart.com
Clene Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - The Manila Times
Breakthrough: Clene's ALS Treatment Shows 11.9-Month Survival Benefit in Severe Cases - Stock Titan
BiomednewsbreaksClene Inc. (NASDAQ: CLNN) Unveils Progress On CNM-Au8(R), Eyes Potential Fast-Track FDA Approval - MENAFN.COM
Bullish Clene Insiders Loaded Up On US$583.4k Of Stock - Yahoo
0.62%
1.39%
자본화:
|
볼륨(24시간):